Sionna Therapeutics (NASDAQ:SION – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by investment analysts at Citizens Jmp in a research note issued on Tuesday,Benzinga reports. They currently have a $63.00 target price on the stock. Citizens Jmp’s price target would indicate a potential upside of 50.21% from the company’s current price.
Several other brokerages have also issued reports on SION. Wall Street Zen lowered Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Citigroup started coverage on Sionna Therapeutics in a research note on Tuesday, February 24th. They set an “outperform” rating for the company. JonesTrading boosted their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Finally, Stifel Nicolaus increased their target price on Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, May 18th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $53.22.
View Our Latest Analysis on Sionna Therapeutics
Sionna Therapeutics Trading Up 2.0%
Sionna Therapeutics (NASDAQ:SION – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Sell-side analysts forecast that Sionna Therapeutics will post -2.57 EPS for the current year.
Insider Transactions at Sionna Therapeutics
In other news, Director Peter A. Thompson sold 235,863 shares of Sionna Therapeutics stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the sale, the director owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. The trade was a 6.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32. Following the completion of the sale, the director owned 3,247,025 shares of the company’s stock, valued at $144,947,196. The trade was a 6.77% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,717,760 shares of company stock worth $77,562,902 over the last 90 days. Insiders own 3.90% of the company’s stock.
Institutional Investors Weigh In On Sionna Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of SION. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics during the 3rd quarter valued at $30,000. BNP Paribas Financial Markets bought a new position in shares of Sionna Therapeutics during the 2nd quarter worth $31,000. GF Fund Management CO. LTD. purchased a new position in shares of Sionna Therapeutics during the fourth quarter valued at $36,000. Balyasny Asset Management L.P. purchased a new position in shares of Sionna Therapeutics during the fourth quarter valued at $58,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Sionna Therapeutics in the fourth quarter valued at about $89,000.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Featured Stories
- Five stocks we like better than Sionna Therapeutics
- Berkshire Sells Visa, Domino’s, and Pool Corp: Should You Follow?
- Why Walmart’s Rally May Need a Reset
- Cloud-flation: Dell’s On-Premise AI Bet Pays Off
- Alphabet Just Unveiled Its Most Ambitious AI Lineup Yet
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
